Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125 -2.13% 5.75 5.70 5.80 5.875 5.75 5.88 695,737 16:26:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 5.7 0.2 0.1 115.0 25

Byotrol Share Discussion Threads

Showing 9251 to 9274 of 10100 messages
Chat Pages: Latest  380  379  378  377  376  375  374  373  372  371  370  369  Older
DateSubjectAuthorDiscuss
30/4/2020
13:11
Melody999 Byot have already stated that they expect the high levels of orders to ease... "Whilst we EXPECT the current very high levels of demand to EASE at some stage over the course of FYE 2021" https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf
sikhthetech
30/4/2020
13:10
Melody999 "the market will start look forward again:." It's not good when a company presented with a huge opportunity is unable to even meet their expectations without Covid-19. It's even more questionable that in the Covid TU, published only a month ago, they stated that they will exceed guidance in the interims... They never published any expectation figures in the interims. Their house broker did, yet they failed to meet those expectations, despite the huge sales due to covid19. "Byotrol's results to 31 March 2020 are now expected to exceed the guidance given at the time of our interim results, where we confirmed our expectations of positive EBITDA for the full year. " https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Byotrol-PLC-Trading-Update/82053342
sikhthetech
30/4/2020
00:49
Not at all, Bought Nivacyt, made a packet Bought Avacta, made a packet Also hold Synairgen which hasn’t risen. Need trial results, could go either way. BYOT has been given a nice boost of momentum but obviously negotiating licence deals doesn’t happen overnight. These will do exceptionally well over the next six months.
a.fewbob
29/4/2020
11:45
A.Fewbobless
brownson
29/4/2020
10:13
Just added more on the dip today
tonytyke
29/4/2020
10:04
May have missed expectations but that is all looking backwards and the market will start look forward again:. From the 270420 TU: Byotrol has been positioning for such trends for many years and expects them to favour technologies like ours, presenting exceptional growth opportunities for the Group. Now expect FY2021 to be one of significant growth in both revenue and EBITDA. And the 230320 TU: Firm orders currently sit at £1.7m for deliveries to end of June, with many more orders still being processed. Historically our order book at this time of year has been around £0.35m
melody9999
29/4/2020
09:36
Joined the party with 40,000 @ 5.2p Registered as a sell, buying at the bid on LSE Fall now reversing
fizzypop
29/4/2020
09:28
3.5p. Are you taking the peez?
loafofbread
29/4/2020
09:22
Weak support at 5.00p else back down to 3.50p.
eeza
29/4/2020
08:55
The rocks being thrown at byotrol’s FY20 performance, in terms of failing to meet broker forecasts and unimpressive year-on-year comparisons, perhaps show why it would be good to get some more granularity into the reporting, either from byotrol itself, or through broker notes. Year-on-year comparisons are complicated by the fact that Medimark was only in for 7 months or so of FY19 but also by the big Solvay contribution booked in FY19. A starting point is perhaps to break down the performance between Medimark and the pre-Medimark business. Medimark is a growing product-sales-based business which is profitable, whereas pre-Medimark, byotrol performance was significantly influenced by individual deals such as the Solvay licensing deal, without which it would have been loss-making (adj EBITDA). In FY19 in particular, I think there was a £1.9m revenue contribution booked from the Solvay deal. Medimark. £2.7m revenue FY18 (year-ending 31/3/2018) £3.0m revenue FY19 (full year, not just post-acquisition) Byotrol (excl Medimark contribution in FY19) £1.8m revenue FY18 (as re-stated in FY19 accounts) £3.9m revenue FY19 (incl £1.9m Solvay) Without the Solvay deal, I think pro-forma Byotrol + Medimark (i.e. including 12 months of Medimark) would have been about £5.0m revenue in FY19. So £6.0m FY20, if it is all from underlying product sales, shows healthy underlying growth, but we do not yet know how much, if any, contribution there is in the FY20 number from “up-front̶1; licensing deals (i.e. non-recurring revenue not related to actual product sales). (Errors excepted)
1gw
28/4/2020
19:38
A.Fewbob, "It’s the forward looking statement that counts." Agree, the forward looking statement is what counts... They state that they have a strong order book for the FIRST QUARTER, ie next TWO months, ending June. Rest is EXPECT, PRESENTING or Jam tomorrow and STILL ASSESSING MANY (not significant) orders. Where's the visibility past next 2 months, Qtr 1 end June.??? Surely they would know if they had strong order book for Q2 as well. Last year, the fy results were published Mid-Oct, although due Sept, so it could be still 5-6 months before there's any more clarity . "We entered the new financial year with a strong order book exceeding £2m and expect to generate record sales from products (i.e. excluding licenses, royalties and technical development deals) in the first quarter of the year." "There are also many additional orders STILL being assessed for deliverability against the supply chain constraints being experienced across our whole industry sector." "Whilst we EXPECT the current very high levels of demand to EASE at some stage over the course of FYE 2021" https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf
sikhthetech
28/4/2020
17:00
Exactly afewbob-just a lightweight trying to deramp. Huge prospects here going forward. MMs will predictably spend a few days just feeding off the weak before they let it go again. With so much happening I don't think the company, or broker, are in a position to give forecasts, nor should mgmt even try at what is the most dynamic time of this company's life. Patience.
cumnor
28/4/2020
16:35
It’s the forward looking statement that counts.
a.fewbob
28/4/2020
16:34
How do??? How do you know that??????? Results were only to mid March you muppet.
a.fewbob
28/4/2020
16:30
They certainly dont seem to have used the massive opportunity presented by covid as much as I hoped. The markets remain unimpressed. There seems to be a lack of dynamism
brownson
28/4/2020
12:07
brownson, "market seems unimpressed" As expected, they missed expectations despite the huge increase in orders due to Covid19. Even though Expectations were EXCLUDING covid19, so excluding Covid19 sales. Actuals INCLUDE Covid19 sales. Period, expectations, actuals Revenue £6m, £6m Adj EBITDA £0.4m £0.25m Cash £2.6m, £1.7m https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf Cash balances have been declining for years.. fy2018 £3.85m fy2019 £2.8m H12020 £2.01m fy2020 £1.7m
sikhthetech
28/4/2020
11:45
Well I bought some more. That’s an extremely upbeat trading statement in a market which is booming and will continue to do so as this covid disease has brought hygiene to the forefront like never before. When procurement stop panic buying and start thinking more carefully they will see that BYOT product is absolutely fantastic!!
a.fewbob
28/4/2020
11:08
The market seems unimpressed.
brownson
28/4/2020
09:15
Any thoughts to why we didn't get a RNS on the 'massive' April deal they mention. As you say, all the heavy lifting has been done. Just a question of signing deals and selling. Well done to the company.
loafofbread
28/4/2020
08:54
Thanks for all your input 1gw,as you say very encouraging and downside risk medium/long term very low.Usual selling after the fact but 2021 figures should be stellar.
riddlerone
28/4/2020
08:03
Just mulling over the TU, I think it would be difficult to imagine a more positive business outlook. This has been reflected at least in part by finnCap raising their target price from 7p to 9p. Clearly it must be very difficult to quantify the outlook in terms of high-confidence revenue and profit expectations given the uncertainties, and perhaps the company felt that it was enough to make the qualitative statements given how positive they were. The company will have a chance to update on 1Q performance and 1H outlook when it publishes FY20 results and by then the supply chain capacity position and demand outlook for the rest of the year may be much clearer. It strikes me, in passing, that the statements below from the TU would not appear out of place in the marketing material for a sale of the company. “We continue to experience exceptional demand…” “…expecting to benefit significantly from a secular shift…” “…expect to generate record sales from products …in the first quarter of the year.” “…also working on a number of longer-term product supply contracts and technology licenses…̶1; “Byotrol has been positioning for such trends for many years and expects them to favour technologies like ours, presenting exceptional growth opportunities for the Group.” “We now expect FY2021 to be one of significant growth in both revenue and EBITDA.” “Our technologies are getting interest from all over the world now. We are increasingly well positioned for further growth post Covid19…”;
1gw
27/4/2020
23:02
Because they’ve been ridiculously busy selling selling selling!
a.fewbob
27/4/2020
22:53
Todays up & downs ??I personally think it's because last years results have not been audited yet Why ?? Are they hiding something ?
georgia103
27/4/2020
22:51
Any guesses at what revenue for the next financial year?
a.fewbob
Chat Pages: Latest  380  379  378  377  376  375  374  373  372  371  370  369  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200812 15:45:17